Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
About 1 in 1,000 pregnant women is diagnosed with cancer. Do newer treatments, such as immunotherapy, work in this group of patients?
“It is a really important development for our patients."
Neoadjuvant Opdivo plus chemotherapy improved outcomes for people with operable non-small-cell lung cancer.
Bill Evans, a melanoma survivor, turns his love of cycling into a community building and fundraising effort.
A combination of two immunotherapy drugs showed efficacy in the treatment of advanced melanoma in a phase 3 clinical trial.
A unique analysis measures treatment-free survival after immunotherapy in patients with advanced renal cell carcinoma.
Opdivo plus relatlimab delayed disease progression compared with Opdivo alone.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.
People diagnosed with advanced melanoma may soon have a new treatment option that combines two immunotherapy drugs.
More people treated with Opdivo plus Yervoy reached the 6.5-year survival mark than those treated with either drug alone.
Checkpoint inhibitor doubled disease-free survival time after surgery.
Opdivo plus chemotherapy led to a significant improvement in overall survival.
However, a majority of these chronic immune-related side effects were mild.
Altering gut bacteria may help overcome resistance to checkpoint inhibitors in people with melanoma and other cancers.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.